Isomorphic Labs Raises 5 Billion Dollars to Move to Clinical Trials
Isomorphic Labs has raised 5 billion dollars in a Series C round to enhance its AI drug design engine and prepare its programs for clinical trials. The company aims to turn preclinical results into human evidence.
Isomorphic Labs announced on November 17, 2026, a 5 billion dollar Series C funding round, co-led by Greenoaks and Sequoia Capital, to accelerate its AI drug design platform and bring its therapeutic candidates closer to clinical trials. This oversubscribed funding provides the company founded around Demis Hassabis with significantly greater resources to move beyond the lab. The real test begins now: transitioning preclinical results to human data without biology causing setbacks.
Une levée massive pour changer d’échelle
The Series C also includes Andreessen Horowitz and several new investors, while Alphabet has increased its stake. All existing investors participated again: Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. In its statement, Isomorphic explains that these funds will be used to develop IsoDDE, its proprietary drug design engine, expand its work into new areas of biology, and build a global infrastructure for AI-driven bioengineering.
IsoDDE, short for Isomorphic Design Engine, combines AI models designed to generate and refine molecules with properties compatible with therapeutic use. Proprietary agents then reason about complex biology, which sums up the sector’s promise: having models compute what human teams previously took much longer to explore. Here, the challenge is not only to find a molecule but to prove it works in a patient.
Du préclinique aux patients, le saut décisif
Demis Hassabis summarized the goal in the funding announcement: “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.” The sentence clearly states the ambition but also the friction point: even solid preclinical progress guarantees nothing until a clinical trial validates it.
Isomorphic says it has positive preclinical results on proprietary oncology and immunology programs, as well as on work conducted with partners. The company now plans to invest in clinical and translational development infrastructure, in other words, the building blocks that allow moving from basic research to medical evaluation. This step matters because it is where many AI promises in health face the reality of protocols, timelines, and regulatory criteria.
Une montée en puissance financée par trois tours successifs
This Series C is part of a rapid funding sequence. Isomorphic announced a 2.1 billion dollar Series B on May 12, 2026, led by Thrive Capital, with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. Before that, Thrive had already led the first external raise of 600 million dollars, announced on March 31, 2025, with GV and follow-on from Alphabet.
The pace reveals a market where a few players concentrate very large tickets on the idea that AI can reduce the time and cost of drug discovery. At this level, investor patience is not exactly a parlor hobby. For Isomorphic, what follows will depend less on the size of the rounds than on the quality of the evidence generated in the clinic.
Des alliances avec Novartis, Eli Lilly et Johnson & Johnson
Beyond its own programs, Isomorphic has built a portfolio of partnerships with Novartis, Eli Lilly, and Johnson & Johnson. The collaboration with Eli Lilly focuses on small molecule therapies targeting undisclosed targets, while the agreement with Johnson & Johnson covers both small molecules and biologics. Novartis has worked with Isomorphic since January 2024 on small molecules against three challenging targets, then expanded this agreement in February 2025 with up to three additional research programs.
This combination of proprietary programs and partnerships gives Isomorphic a broader working base than a simple software startup. In practice, the company tries to position itself as a pharmaceutical discovery infrastructure, not just a tool provider. It remains to be seen whether this architecture will ultimately produce drugs capable of crossing the final hurdle.
By the numbers
- 5 billion dollars — Series C announced on November 17, 2026, Isomorphic Labs.
- 2.1 billion dollars — Series B announced on May 12, 2026, led by Thrive Capital.
- 600 million dollars — first external raise announced on March 31, 2025, led by Thrive.
- 3 targets — Novartis program launched in January 2024.
- Up to 3 programs — Novartis agreement extension in February 2025.